NITD008 explained
| Iupac Name: | (2R,3R,4R,5R)-2-(4-Amino-7H-pyrrolo[2,3-''d'']pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
| Tradename: | NITD008 |
| Cas Number: | 1044589-82-3 |
| Pubchem: | 44633776 |
| Unii: | LKI7T3WQ2E |
| Chemspiderid: | 26376187 |
| Chembl: | 1630221 |
| C: | 13 |
| H: | 14 |
| N: | 4 |
| O: | 4 |
| Smiles: | C#C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC3=C2N=CN=C3N)CO)O)O |
| Stdinchi: | 1S/C13H14N4O4/c1-2-13(20)9(19)8(5-18)21-12(13)17-4-3-7-10(14)15-6-16-11(7)17/h1,3-4,6,8-9,12,18-20H,5H2,(H2,14,15,16)/t8-,9-,12-,13-/m1/s1 |
| Stdinchikey: | NKRAIOQPSBRMOV-NRMKKVEVSA-N |
NITD008 is an antiviral drug classified as an adenosine analog (a type of nucleoside analog). It was developed as a potential treatment for flavivirus infections and shows broad spectrum antiviral activity against many related viruses such as dengue virus, West Nile virus, yellow fever virus, Powassan virus, hepatitis C virus, Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Zika virus.[1] [2] [3] However, NITD008 proved too toxic in pre-clinical animal testing to be suitable for human trials, but it continues to be used in research to find improved treatments for emerging viral diseases.[4]
See also
- Favipiravir, a drug approved by China, Germany, Indonesia, Iran, Japan, Thailand, and Turkey for treating COVID-19 patients
- MK-608, a drug with a similar structure
- Remdesivir, FDA approved antiviral drug with a similar structure
- Ribavirin, another antiviral drug with teratogenic side effects that was patented by Merck in 1971 and approved by the FDA in 1986
Notes and References
- Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY . 6 . An adenosine nucleoside inhibitor of dengue virus . Proceedings of the National Academy of Sciences of the United States of America . 106 . 48 . 20435–9 . December 2009 . 19918064 . 10.1073/pnas.0907010106 . 2787148 . free . 2009PNAS..10620435Y .
- Lo MK, Shi PY, Chen YL, Flint M, Spiropoulou CF . In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses . Antiviral Research . 130 . 46–9 . June 2016 . 27016316 . 5096641 . 10.1016/j.antiviral.2016.03.013 .
- Deng YQ, Zhang NN, Li CF, Tian M, Hao JN, Xie XP, Shi PY, Qin CF . 6 . Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus . Open Forum Infectious Diseases . 3 . 4 . ofw175 . October 2016 . 27747251 . 10.1093/ofid/ofw175 . 5063548 . free .
- Nelson J, Roe K, Orillo B, Shi PY, Verma S . Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection . Antiviral Research . 122 . 39–45 . October 2015 . 26225754 . 4853296 . 10.1016/j.antiviral.2015.07.008 .
